Start main content
Back

May 02, 2019

Seminar - Mass Cytometry, a Must-Have for a Master (Speaker: Professor Guo Fu)

Professor Guo Fu
School of Life Sciences, Xiamen University, Fujian, China

Date: Thursday, 2-May-2019
Time: 4:00 p.m.
Venue: Seminar Room 4, G/F, Laboratory Block
Faculty of Medicine Building
21 Sassoon Road, Pokfulam, Hong Kong

Summary:
For decades, fluorescent flow cytometry has been the standard technique for immunology and other research fields. However, the limited numbers and the spillovers of fluorescent channels are two main barriers for high-dimensional analysis when using fluorescent flow cytometry. The recent launch of Mass Cytometry or cytometry by time of flight (CyTOF) has revolutionized flow cytometry by tackling these challenges, and enables the maximal usage of valuable clinical samples. In this seminar, Professor Fu will discuss the development of new reagents and protocols compatible for mass cytometry analysis. He will also discuss the pros and cons of mass cytometry technology based on their research experience. For example, by employing in vitro Blinatumomab cytotoxicity assay, and high-dimensional mass cytometry-based deep profiling of patient PBMCs samples, they found that T cell production of IL-2, IFN-g, perforin, granzyme B, and CCL4 strongly correlated with sensitivity to Blinatumomab-mediated cytotoxicity. They further demonstrated in a human B-ALL xenograft mouse model that a Blinatumomab and CCL4 combination therapy is more effective than Blinatumomab alone at clearing leukemia cells from the bone marrow, a primary hiding niche for leukemic cells. Their results suggest that the combination therapy of Blinatumomab and CCL4 is a better treat regimen for patients with B-ALL.

ALL ARE WELCOME